Vyzulta (Latanoprostene Bunod) Patent Expiration, LOE Window & CMS Spending

Vyzulta (Latanoprostene Bunod) by Bausch Health: FDA Orange Book core substance LOE 2029-02-21, 1 AB generics, $133.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN207795 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-02-21
Last Listed Patent or Exclusivity Date2029-02-21
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$133.8M
2024 Medicare Part D Spend$128.3M
2024 Medicaid Spend$5.5M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.